



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

July– September 2006

Warrington DAT

Quarter 2 2006/07

**Martin Chandler, Esther Shepherd,
Jim McVeigh, Adam Marr and Paul Duffy**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:

Martin Chandler

IAD Manager

Centre for Public Health

Faculty of Health & Applied Social Sciences

Liverpool John Moores University

Castle House

North Street

L3 2AY

(0151) 231 4531

m.chandler@ljmu.ac.uk

Esther Shepherd

IAD Researcher

(0151) 231 4521

e.shepherd@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Probation	5
Table 4: Probation clients by Gender and Age Group	
Table 5: Year to Date, by Gender and Age Group	
Table 6: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange Services	7
Agency	
Table 7: Individuals by Gender	
Table 8: Individuals by Gender: Steroid Users omitted	
Table 9: Individuals by Age Group	
Table 10: Individuals by Age Group: Steroid Users omitted	
Table 11: Gender by Age Group of Individuals	
Table 12: Gender by Age Group: Steroid Users omitted	
Table 13: Year to Date, by Gender & Age Group	
Table 14: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 16: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	12
Table 17: Individuals by Gender	
Table 18: Individuals by Age Group	
Table 19: Year to Date, by Gender & Age Group	
Combined	14
Table 20: Individuals in Syringe Exchange, by Gender	
Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 22: Individuals in Syringe Exchange, by Age Group	
Table 23: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 24: Year to Date, by Gender & Age Group	
Table 25: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 16

Table 26: Individuals in contact with Treatment Services, by Gender

Table 27: Year to Date, by Gender

Table 28: Individuals in contact with Treatment Services, by Age Group

Table 29: Year to Date, by Age Group

Table 30: Ethnicity of Individuals in Contact with Treatment Services

Table 31: Individuals in contact with Treatment Services, by Main Drug of Use

Combined Datasets 19

Table 32: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 33: Year to Date, by Gender & Age Group

Cross Matched Datasets 20

Fig 1: Crossover between Agency and Pharmacy Syringe Exchange and NDTMS datasets.

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 2 (2006/07)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	21	100
Female	0	0
Age Group		
Under 18	0	0
18-19	2	9.5
20-24	3	14.3
25-29	5	23.8
30-34	7	33.3
35-39	1	4.8
40-44	1	4.8
45+	2	9.5
Total	21	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	4	11.1	0	0	4	11.1
20-24	5	13.9	0	0	5	13.9
25-29	7	19.4	0	0	7	19.4
30-34	10	27.8	0	0	10	27.8
35-39	5	13.9	0	0	5	13.9
40-44	3	8.3	0	0	3	8.3
45+	2	5.6	0	0	2	5.6
Total	36	100	0	0	36	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	1
Benzodiazepines	1	0
Cannabis	3	0
Crack	5	1
Cocaine	0	1
Ecstasy	0	0
Heroin	7	1
Methadone	1	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 2 (2006/07)

Introduction

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

NOTE: Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets.

Table 4: Probation Clients by Gender and Age Group

Gender	n	%
Male	80	89.9
Female	9	10.1
Age Group		
Under 18	0	0
18-19	7	7.9
20-24	19	21.3
25-29	13	14.6
30-34	13	14.6
35-39	9	10.1
40-44	15	16.9
45+	13	14.6
Total	89	100

Table 5: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	10	8.8	0	0	10	7.8
20-24	23	20.4	2	12.5	25	19.4
25-29	20	17.7	4	25.0	24	18.6
30-34	24	21.2	3	18.8	27	20.9
35-39	12	10.6	1	6.3	13	10.1
40-44	12	10.6	4	25.0	16	12.4
45+	12	10.6	2	12.5	14	10.9
Total	113	100	16	100	129	100

Table 6: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	1
Benzodiazepines	0	0
Cannabis	1	2
Crack	1	0
Cocaine	1	0
Ecstasy	0	1
Heroin	2	0
Steroids	1	0
Methadone	0	0
Other Opiate	0	0

NB: Table 6 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

SYRINGE EXCHANGE SERVICES

Quarter 2 (2006/07)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level. This also facilitates geographical analysis of both distribution and movement of injecting drug users.

AGENCY SYRINGE EXCHANGE

Table 7: Individuals by Gender

New Clients	n	%
Male	15	88.2
Female	2	11.8
<i>Total</i>	<i>17</i>	<i>100</i>
All Clients		
Male	195	94.2
Female	12	5.8
<i>Total</i>	<i>207</i>	<i>100</i>

Table 8: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	5	71.4
Female	2	28.6
<i>Total</i>	<i>7</i>	<i>100</i>
All Clients		
Male	71	85.5
Female	12	14.5
<i>Total</i>	<i>83</i>	<i>100</i>

Table 9: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	1	5.9	4	1.9
20-24	6	35.3	36	17.4
25-29	2	11.8	41	19.8
30-34	2	11.8	58	28.0
35-39	4	23.5	37	17.9
40-44	1	5.9	16	7.7
45+	1	5.9	15	7.2
<i>Total</i>	<i>17</i>	<i>100</i>	<i>207</i>	<i>100</i>

Table 10: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	2	28.6	10	12.0
25-29	0	0	6	7.2
30-34	2	28.6	30	36.1
35-39	3	42.9	21	25.3
40-44	0	0	9	10.8
45+	0	0	7	8.4
Total	7	100	83	100

Table 11: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	4	2.1	0	0
20-24	34	17.4	2	16.7
25-29	40	20.5	1	8.3
30-34	53	27.2	5	41.7
35-39	35	17.9	2	16.7
40-44	15	7.7	1	8.3
45+	14	7.2	1	8.3
Total	195	100	12	100

Table 12: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	8	11.3	2	16.7
25-29	5	7.0	1	8.3
30-34	25	35.2	5	41.7
35-39	19	26.8	2	16.7
40-44	8	11.3	1	8.3
45+	6	8.5	1	8.3
Total	71	100	12	100

Table 13: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0	0	0	0	0
18-19	6	1.9	1	4.0	7	2.0
20-24	64	19.8	5	20.0	69	19.8
25-29	68	21.1	3	12.0	71	20.4
30-34	83	25.7	8	32.0	91	26.1
35-39	58	18.0	5	20.0	63	18.1
40-44	24	7.4	2	8.0	26	7.5
45+	20	6.2	1	4.0	21	6.0
Total	323	100	25	100	348	100

Table 14: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender					
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	0	0	1	4.0	1	0.7
20-24	12	10.7	5	20.0	17	12.4
25-29	11	9.8	3	12.0	14	10.2
30-34	39	34.8	8	32.0	47	34.3
35-39	29	25.9	5	20.0	34	24.8
40-44	12	10.7	2	8.0	14	10.2
45+	9	8.0	1	4.0	10	7.3
Total	112	100	25	100	137	100

Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0	0	0
Benzodiazepines	0	0	0	0
Cocaine	0	0	0	0
Crack	0	0	0	0
Heroin	5	33.3	2	100
Methadone	0	0	0	0
Steroids	10	66.7	0	0
Total	15	100	2	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 16: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Heroin		Steroids	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	1	10.0
20-24	2	28.6	4	40.0
25-29	0	0	2	20.0
30-34	2	28.6	0	0
35-39	3	42.9	1	10.0
40-44	0	0	1	10.0
45+	0	0	1	10.0
Total	7	100	10	100

PHARMACY SYRINGE EXCHANGE

Please Note: Due to data provision issues, only data from July is provided here.

Table 17: Individuals by Gender

New Clients	n	%
Male	0	0
Female	0	0
<i>Total</i>	<i>0</i>	<i>0</i>
All Clients		
Male	62	86.1
Female	10	13.9
Total	72	100

Table 18: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	2	2.8
20-24	0	0	7	9.7
25-29	0	0	16	22.2
30-34	0	0	21	29.2
35-39	0	0	14	19.4
40-44	0	0	8	11.1
45+	0	0	4	5.6
Total	0	0	72	100

Table 19: Year to Date, by Gender & Age Group

Age Group	Gender					
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	5	3.9	0	0	5	3.5
20-24	28	21.9	0	0	28	19.4
25-29	21	16.4	5	31.3	26	18.1
30-34	36	28.1	4	25.0	40	27.8
35-39	25	19.5	5	31.3	30	20.8
40-44	8	6.3	1	6.3	9	6.3
45+	5	3.9	1	6.3	6	4.2
Total	128	100	16	100	144	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 20: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	15	88.2
Female	2	11.8
<i>Total</i>	<i>17</i>	<i>100</i>
All Clients		
Male	249	92.2
Female	21	7.8
Total	270	100

Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	5	71.4
Female	2	28.6
<i>Total</i>	<i>7</i>	<i>100</i>
All Clients		
Male	125	85.6
Female	21	14.4
Total	146	100

Table 22: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	1	5.9	6	2.2
20-24	6	35.3	42	15.6
25-29	2	11.8	56	20.7
30-34	2	11.8	75	27.8
35-39	4	23.5	49	18.1
40-44	1	5.9	23	8.5
45+	1	5.9	19	7.0
Total	17	100	270	100

Table 23: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	2	1.4
20-24	2	28.6	16	11.0
25-29	0	0	21	14.4
30-34	2	28.6	47	32.2
35-39	3	42.9	33	22.6
40-44	0	0	16	11.0
45+	0	0	11	7.5
Total	7	100	146	100

Table 24: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	11	2.6	1	2.6	12	2.6
20-24	87	20.5	6	15.4	93	20.0
25-29	86	20.2	7	17.9	93	20.0
30-34	110	25.9	10	25.6	120	25.9
35-39	75	17.6	10	25.6	85	18.3
40-44	31	7.3	3	7.7	34	7.3
45+	25	5.9	2	5.1	27	5.8
Total	425	100	39	100	464	100

Table 25: Total Syringes Provided

	This Quarter	Year to Date
Barrels	11,176	27,767
Needles	19,132	43,116

NB: Non-attributable data is included to provide the syringe totals. We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available.

National Drug Treatment Monitoring System (NDTMS)

Quarter 2 (2006/07)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 26: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	63	75.0
Female	21	25.0
<i>Total</i>	<i>84</i>	<i>100</i>
All Clients		
Male	574	74.6
Female	196	25.5
<i>Total</i>	<i>770</i>	<i>100</i>

Table 27: Year to Date, by Gender

New Clients	n	%
Male	118	77.1
Female	35	22.9
<i>Total</i>	<i>153</i>	<i>100</i>
All Clients		
Male	597	75.2
Female	197	24.8
<i>Total</i>	<i>794</i>	<i>100</i>

Table 28: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	10	11.9	51	6.6
18-19	5	6.0	18	2.3
20-24	12	14.3	63	8.2
25-29	13	15.5	128	16.6
30-34	20	23.8	211	27.4
35-39	12	14.3	164	21.3
40-44	8	9.5	80	10.4
45+	4	4.8	55	7.1
Total	84	100	770	100

Table 29: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	18	11.8	60	7.6
18-19	6	3.9	24	3.0
20-24	19	12.4	77	9.7
25-29	31	20.3	184	23.2
30-34	29	19.0	217	27.3
35-39	25	16.3	142	17.9
40-44	17	11.1	51	6.4
45+	8	5.2	39	4.9
Total	153	100	794	100

Table 30: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	83	98.8	760	98.7
White Irish	0	0	2	0.3
Other White	0	0	0	0
White & Black Caribbean	0	0	0	0
White & Black African	0	0	0	0
White & Asian	0	0	1	0.1
Other Mixed	0	0	1	0.1
Other Asian	0	0	0	0
Caribbean	0	0	0	0
African	0	0	0	0
Other Black	0	0	2	0.3
Chinese	0	0	0	0
Other	1	1.2	4	0.5
Unknown	0	0	0	0
Total	84	100	770	100

Table 31: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Amphetamine	3	3.6	19	2.5
Benzodiazepine	0	0	7	0.9
Cannabis	12	14.3	118	15.3
Cocaine	8	9.5	47	6.1
Crack	3	3.8	20	2.6
Heroin	43	51.2	433	56.2
Methadone	8	9.5	86	11.2
Other Opiates	4	4.8	24	3.1
Ecstasy	0	0	8	1.0
Solvents	0	0	1	0.1
Other/Unknown	3	3.6	7	0.9
Total	84	100	770	100

COMBINED DATASETS

Quarter 2 (2006/07)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 32: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	864	80.1
Female	215	19.9
Age Group		
Under 18	60	5.6
18-19	38	3.5
20-24	133	12.3
25-29	239	22.2
30-34	283	26.2
35-39	180	16.7
40-44	83	7.7
45+	63	5.8
Total	1079	100

Table 33: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	43	4.0	17	7.5	60	4.6
18-19	43	4.0	6	2.6	49	3.8
20-24	166	15.5	28	12.3	194	14.9
25-29	225	21.0	58	25.6	283	21.8
30-34	268	25.0	53	23.3	321	24.7
35-39	183	17.1	37	16.3	220	16.9
40-44	77	7.2	19	8.4	96	7.4
45+	67	6.3	9	4.0	76	5.9
Total	1072	100	227	100	1299	100

CROSS-MATCHED DATASETS

Quarter 2 (2006/07)

Data from Agency and Pharmacy Syringe Exchange and NDTMS were cross-matched to each other to reveal the number of clients accessing more than one of these services during the current reported quarter.

For the purposes of this analysis, known steroid users were removed as they are unlikely to be accessing structured drug treatment.

NB: Numbers in brackets refer to the total reported for that service type. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site. The crossover between Agency and Pharmacy Syringe Exchange is based on the D(A)AT of Agency as this is the more robust dataset.

Fig 1: Crossover between Agency and Pharmacy Syringe Exchange, and NDTMS datasets

